NCT02109289View on ClinicalTrials.gov

Etanercept in Rheumatoid Arthritis and Vascular Inflammation

PHASE4TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Rheumatoid ArthritisVascular Inflammation
Interventions
DRUG

etanercept

Etanercept is a tumor necrosis factor antagonist

Trial Locations (1)

H2L 1S6

Institut de rhumatologie de Montreal, Montreal

Sponsors
All Listed Sponsors
lead

Innovaderm Research Inc.

OTHER